GE HealthCare Secures FDA, CE Clearances and First Install for AI-Guided Allia Moveo
GE HealthCare's Allia Moveo mobile C-arm secured FDA 510(k) clearance and CE Mark, enabling U.S. and European commercialization. The company completed the first global installation of the AI-guided, compact Allia Moveo system to enhance interventional suite mobility and precision imaging.
1. Q4 Profit Declines Despite Revenue Growth
GE HealthCare reported fourth-quarter revenues of $5.7 billion, a 7.1% increase over the prior year driven by strength in Pharmaceutical Diagnostics, Imaging and Advanced Visualization Solutions. Despite the top-line gain, net income attributable to the company fell to $589 million from $720 million a year earlier, and diluted EPS declined to $1.29 from $1.57. Adjusted EBIT dipped to $950 million versus $994 million, as higher tariff expenses and an unfavorable product mix more than offset benefits from volume growth and pricing initiatives.
2. Segment Performance Highlights
Imaging revenues rose 6.6% year-over-year to $2.552 billion, delivering segment EBIT of $264 million but with a margin contraction of 230 basis points to 10.4%. Advanced Visualization Solutions generated $1.525 billion in sales, up 5.9%, and segment EBIT held flat at $376 million with a 24.7% margin. Patient Care Solutions saw a slight revenue decline to $825 million, while Pharmaceutical Diagnostics surged 22.3% to $790 million, driving a 10% increase in segment EBIT to $234 million despite a 330 basis-point margin pullback.
3. Full Year Results and Capital Deployment
For the full year, revenues reached $20.6 billion, up 4.8% including 3.5% organic growth, with net income of $2.1 billion compared with $2.0 billion in the prior year. Adjusted EPS climbed to $4.59 from $4.49, reflecting stronger earnings and operational resilience against $200 million of tariff headwinds. Free cash flow for 2025 totaled $1.5 billion, cash and equivalents stood at $4.5 billion, and capital expenditures rose to $482 million. GE HealthCare returned capital via $200 million in share repurchases and maintained a quarterly dividend of $0.035 per share.
4. 2026 Outlook and Strategic Priorities
GE HealthCare projects 2026 organic revenue growth of 3.0%–4.0% and adjusted EPS in the range of $4.95 to $5.15, implying up to 12.3% growth year-over-year. The company aims to expand adjusted EBIT margin by 50–80 basis points to as much as 16.1% and generate approximately $1.7 billion in free cash flow. Management will focus on precision care innovations, continued rollout of its Heartbeat productivity system, margin expansion and the planned acquisition of Intelerad to bolster its cloud-enabled enterprise imaging platform.